JP2022515487A - クローディン１８．２結合部分およびその利用 - Google Patents

クローディン１８．２結合部分およびその利用 Download PDF

Info

Publication number
JP2022515487A
JP2022515487A JP2021537771A JP2021537771A JP2022515487A JP 2022515487 A JP2022515487 A JP 2022515487A JP 2021537771 A JP2021537771 A JP 2021537771A JP 2021537771 A JP2021537771 A JP 2021537771A JP 2022515487 A JP2022515487 A JP 2022515487A
Authority
JP
Japan
Prior art keywords
amino acid
seq
nos
acid sequences
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021537771A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020135674A5 (enExample
Inventor
リュウソン、イン
チーリン、ゾウ
ズオ、ファン
ヨン、リウ
チューチュアン、ヂゥアン
ボー、ウー
シャオフー、ファン
チンシャン、チャン
ダン、ザオ
ジエ、マオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of JP2022515487A publication Critical patent/JP2022515487A/ja
Publication of JPWO2020135674A5 publication Critical patent/JPWO2020135674A5/ja
Priority to JP2024103100A priority Critical patent/JP7724332B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021537771A 2018-12-28 2019-12-27 クローディン１８．２結合部分およびその利用 Pending JP2022515487A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024103100A JP7724332B2 (ja) 2018-12-28 2024-06-26 クローディン１８．２結合部分およびその利用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018125052 2018-12-28
CNPCT/CN2018/125052 2018-12-28
CNPCT/CN2019/095827 2019-07-12
CN2019095827 2019-07-12
PCT/CN2019/129017 WO2020135674A1 (en) 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024103100A Division JP7724332B2 (ja) 2018-12-28 2024-06-26 クローディン１８．２結合部分およびその利用

Publications (2)

Publication Number Publication Date
JP2022515487A true JP2022515487A (ja) 2022-02-18
JPWO2020135674A5 JPWO2020135674A5 (enExample) 2022-11-24

Family

ID=71127698

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021537771A Pending JP2022515487A (ja) 2018-12-28 2019-12-27 クローディン１８．２結合部分およびその利用
JP2024103100A Active JP7724332B2 (ja) 2018-12-28 2024-06-26 クローディン１８．２結合部分およびその利用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024103100A Active JP7724332B2 (ja) 2018-12-28 2024-06-26 クローディン１８．２結合部分およびその利用

Country Status (12)

Country Link
US (1) US12258418B2 (enExample)
EP (1) EP3902839A4 (enExample)
JP (2) JP2022515487A (enExample)
KR (1) KR20210110339A (enExample)
CN (1) CN113227146B (enExample)
AU (1) AU2019415848A1 (enExample)
BR (1) BR112021012608A2 (enExample)
CA (1) CA3125193A1 (enExample)
IL (1) IL284393A (enExample)
MX (1) MX2021007939A (enExample)
SG (1) SG11202106534RA (enExample)
WO (1) WO2020135674A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138414A1 (en) * 2019-05-16 2020-11-19 Qilu Pharmaceutical Co., Ltd. Antibodyagainst claudin 18a2 and use thereof
PE20221459A1 (es) 2019-11-05 2022-09-21 Lanova Medicines Ltd Conjugados anticuerpo-farmaco dirigido a claudina 18.2
CN113637082A (zh) * 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
US12492252B2 (en) 2020-07-01 2025-12-09 Shandong Boan Biotechnology Co., Ltd. Anti-GPC3 antibody, anti-GPC3 chimeric antigen receptor and GPC3/CD3 bispecific antibody
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
US20240270839A1 (en) * 2020-09-28 2024-08-15 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
CN114560941B (zh) * 2020-11-27 2024-01-16 广东东阳光药业股份有限公司 Cldn18.2的抗体及其应用
CN114539402B (zh) * 2020-11-27 2025-06-13 南京北恒生物科技有限公司 靶向Claudin18.2的抗体及其用途
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
PE20231561A1 (es) 2020-12-23 2023-10-03 Sotio Biotech A S Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2
CN113321730B (zh) * 2021-01-11 2023-10-10 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用
CN116940598A (zh) * 2021-02-08 2023-10-24 山东博安生物技术股份有限公司 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
CN115109154A (zh) * 2021-03-17 2022-09-27 三优生物医药(上海)有限公司 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
CN117083299A (zh) * 2021-04-02 2023-11-17 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
JP7675818B2 (ja) * 2021-05-08 2025-05-13 レメゲン シーオー．，エルティーディー． 抗クローディン－１８．２抗体及びその抗体薬物複合体
KR20230132640A (ko) 2022-03-04 2023-09-15 앱티스 주식회사 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법
WO2024096564A1 (ko) 2022-11-01 2024-05-10 앱티스 주식회사 항-클라우딘18.2 항체를 포함하는 항체-약물 컨쥬게이트 및 이의 암에 대한 치료용도
TW202434307A (zh) 2023-01-18 2024-09-01 大陸商泰勵生物科技（上海）有限公司 抗體偶聯藥物及其用途
CN116284224B (zh) * 2023-05-12 2023-07-25 中国农业大学 一种结合Claudin 18.2的环肽及其应用
WO2025038602A1 (en) * 2023-08-14 2025-02-20 Ginkgo Bioworks, Inc. Immune cell stimulatory sequences
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025072299A1 (en) * 2023-09-25 2025-04-03 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
CN120829517A (zh) * 2024-04-22 2025-10-24 鲁南新时代生物技术有限公司 抗cldn18.2/cd3双特异性抗体及用途
WO2025251228A1 (en) 2024-06-05 2025-12-11 Nuwacell Biotechnologies Co., Ltd. Cldn18.2-targeting chimeric antigen receptor and engineered cell

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517354A (ja) * 2005-11-24 2009-04-30 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８に対するモノクローナル抗体
JP2016510721A (ja) * 2013-02-20 2016-04-11 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
JP2017522024A (ja) * 2014-07-17 2017-08-10 科済生物医薬（上海）有限公司 Ｃｌｄ１８ａ２標的免疫エフェクター細胞及びその調製方法と使用
JP2018513146A (ja) * 2015-04-15 2018-05-24 ガニメド ファーマシューティカルズ ゲーエムベーハー クローディン１８．２に対する抗体を含む薬物コンジュゲート
JP2018524273A (ja) * 2015-05-11 2018-08-30 ビオエンテッヒ・セル・アンド・ジーン・セラピーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢｉｏｎｔｅｃｈ Ｃｅｌｌ ＆ Ｇｅｎｅ Ｔｈｅｒａｐｉｅｓ Ｇｍｂｈ クローディン−１８．２−特異的免疫受容体およびｔ細胞エピトープ
JP2021517888A (ja) * 2018-05-18 2021-07-29 ラノバ メディシンズ リミテッド カンパニー 抗クローディン１８．２抗体およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
BR112019000327A8 (pt) * 2016-07-08 2022-10-18 Carsgen Therapeutics Co Ltd Anticorpo para anticlaudina 18a2 e uso do mesmo
IL276830B2 (en) * 2018-03-08 2025-08-01 Phanes Therapeutics Inc Anti-claudin 18.2 antibodies and uses thereof
EP3917564A4 (en) * 2019-02-01 2022-12-21 NovaRock Biotherapeutics, Ltd. ANTI-CLAUDINE 18 ANTIBODIES AND THEIR METHODS OF USE
US20220306765A1 (en) * 2019-08-20 2022-09-29 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-cldn18.2 antibodies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517354A (ja) * 2005-11-24 2009-04-30 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８に対するモノクローナル抗体
JP2016510721A (ja) * 2013-02-20 2016-04-11 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
JP2017522024A (ja) * 2014-07-17 2017-08-10 科済生物医薬（上海）有限公司 Ｃｌｄ１８ａ２標的免疫エフェクター細胞及びその調製方法と使用
JP2018513146A (ja) * 2015-04-15 2018-05-24 ガニメド ファーマシューティカルズ ゲーエムベーハー クローディン１８．２に対する抗体を含む薬物コンジュゲート
JP2018524273A (ja) * 2015-05-11 2018-08-30 ビオエンテッヒ・セル・アンド・ジーン・セラピーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢｉｏｎｔｅｃｈ Ｃｅｌｌ ＆ Ｇｅｎｅ Ｔｈｅｒａｐｉｅｓ Ｇｍｂｈ クローディン−１８．２−特異的免疫受容体およびｔ細胞エピトープ
JP2021517888A (ja) * 2018-05-18 2021-07-29 ラノバ メディシンズ リミテッド カンパニー 抗クローディン１８．２抗体およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J HEMATOL ONCOL, vol. 10, no. 1, JPN6023043658, 12 May 2017 (2017-05-12), pages 105 - 1, ISSN: 0005270018 *

Also Published As

Publication number Publication date
CA3125193A1 (en) 2020-07-02
BR112021012608A2 (pt) 2021-09-08
MX2021007939A (es) 2021-10-22
KR20210110339A (ko) 2021-09-07
EP3902839A1 (en) 2021-11-03
US20220073643A1 (en) 2022-03-10
AU2019415848A1 (en) 2021-08-19
US12258418B2 (en) 2025-03-25
CN113227146B (zh) 2024-03-01
JP2024125370A (ja) 2024-09-18
IL284393A (en) 2021-08-31
CN113227146A (zh) 2021-08-06
JP7724332B2 (ja) 2025-08-15
SG11202106534RA (en) 2021-07-29
WO2020135674A1 (en) 2020-07-02
AU2019415848A8 (en) 2021-09-02
EP3902839A4 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
JP7724332B2 (ja) クローディン１８．２結合部分およびその利用
US11897967B2 (en) Humanized anti-MUC1* antibodies
CN113195542B (zh) Cd30-结合部分、嵌合抗原受体及其用途
EP3575322A1 (en) Anti-pd-1 monoclonal antibody, and preparation method therefor and application thereof
TW202023611A (zh) 針對ｃｌｄｎ１８．２和ｃｄ３之抗體構建體
TW202342540A (zh) 用於癌之治療的細胞傷害誘導治療劑
JP2020501586A (ja) がんの処置のための抗ｔｎｆ関連アポトーシス誘発リガンド受容体２及び抗カドヘリン１７結合性二重特異的分子
CN116925233A (zh) 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
KR20240046224A (ko) 이중특이성 항체 및 그 용도
CN117222672A (zh) 抗cldn4-抗cd137双特异性抗体
US20230136252A1 (en) Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
EP4613774A1 (en) Single domain antibody targeting human ror1
EA047760B1 (ru) Группы, связывающие клаудин 18.2, и их использование
WO2026002239A1 (zh) 靶向cd155的抗原结合蛋白及其应用
WO2025228351A1 (zh) 抗体，抗体药物偶联物及其用途
TW202400232A (zh) 多特異性分子與免疫檢查點抑制劑之組合
WO2024114410A1 (zh) 靶向gpc3的抗体及其用途
HK40088437B (zh) 抗cd70纳米抗体及其用途
HK40088437A (zh) 抗cd70纳米抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240628